Year-to date Dupixent sales surpass all of 2021

In just nine months, Sanofi and Regeneron’s Dupixent has come close to reaching another revenue milestone – by the end of the year, the atopic dermatitis treatment will likely be a blockbuster eight times over.

Photo: Af Benoit Tessier / Reuters / Ritzau Scanpix

In the third quarter, Sanofi built on an already successful year, especially when it comes to sales of Dupixent (dupilumab), which is developed in collaboration with Regeneron.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs